NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Can Vitamin D Reduce the Burden of COVID-19?

CompletedNA

Sponsor: University of Chicago

Conditions: COVID-19

Interventions: Vitamin D 400IU, Vitamin D 4000IU

Countries: United States

The purpose of this study is to compare the risks of COVID-19 in individuals from the Chicagoland area and other communities in the United States randomized to low (400 IU/day) versus moderate (4,000 IU/day) dose vitamin D.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

Subjects are able to participate if they:

1. Are 18 years or older.
2. Live in the United States.
3. Are interested in vitamin D as a potential preventive measure against COVID-19 in which they self-administer a daily dose of vitamin D during the 12-month study period.
4. Are willing to complete self-report measures at 5 time points over the course of 12 months by completing a 15-minute survey at intake via web and 10-minute web-based follow-up surveys.

Exclusion Criteria:

Subjects are excluded from study participation if they:

1. Report being pregnant, planning to become pregnant, and/or report breastfeeding during the study period.
2. Report a history of chronic kidney disease, including a history of abnormal GFR and/or creatinine.
3. Report a history of hyperparathyroidism.
4. Report a history of increased falls.
5. Report a history of hypercalcemia.
6. Report a history of gastrointestinal absorptive disorders, including having undergone bariatric surgery.
7. Report a history of kidney stones (1 in past year or 2 in lifetime).
8. Report already taking more than 400 IU of vitamin D daily as recommended by their health care provider, excluding multivitamins and excluding supplements that include vitamin D and calcium together.
9. Report taking D2.
10. Report a history of sarcoidosis.

Locations (1)

Chicago, Illinois, United States